Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Best Buy Co Inc (BBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Best Buy Co Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Best Buy Co Inc trades at $82.17 (market cap $17.45B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.3× Best Buy Co Inc's market cap, and Best Buy Co Inc pays a 4.64% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BBY | |
|---|---|---|
Market Cap | $39.89B | $17.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $84.00 |
52-Week Low | $278.09 | $55.52 |
Enterprise Value | $38.15B | $19.83B |
Dividend Yield | — | 4.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Best Buy (BBY) trades at $82.80, up 3.51% with a bullish technical signal. The stock shows strong profitability with a 39.1% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights strategic shifts under new CEO Jason Bonfig toward higher-margin services like retail media and marketplace expansion, alongside new product launches such as RGB LED TVs and Meta VR partnerships.
Outlook remains cautiously optimistic with a consensus price target of $82.18. The attractive 4.6% dividend yield and improving cash flow support income investors, but risks include macroeconomic pressures on consumer electronics spending and leadership transitions. Revenue declines since 2022 require monitoring for stabilization under new growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →
